Status:

ACTIVE_NOT_RECRUITING

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Conditions:

Brain Cancer

Pituitary Adenoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, can be used to take pictures of brain tumors. The investigators want to understand how the particles ar...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Histologically confirmed diagnosis of malignant primary brain tumor clinical and radiographic findings consistent with a pituitary adenoma, or known metastatic cancer with brain lesion presumed to be metastatic.
  • Normal baseline cardiac function based upon pre-operative evaluation at the physcian's discretion
  • All patients of childbearing age must use an acceptable form of birth control
  • Women who are pre-menopausal must have a negative serum pregnancy test

Exclusion

  • Known pregnancy or breast-feeding Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer
  • °This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease
  • More than one metastatic cancer active in the last 5 years
  • Active metastatic cancer in addition to malignant primary brain tumor
  • Weight greater than the 400-lb weight limit of the PET scanner
  • Unmanageable claustrophobia
  • Inability to lie in the scanner for 30 minutes

Key Trial Info

Start Date :

March 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2026

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT03465618

Start Date

March 7 2018

End Date

March 1 2026

Last Update

January 7 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors | DecenTrialz